Legend Biotech Announces US FDA Clearance of IND Application for Solid Tumor CAR-T, LB1908 for Relapsed or Refractory Gastric, Esophageal and Pancreatic Cancers

Legend Biotech Corporation announced that the US FDA has cleared its investigational new drug (IND) application to evaluate LB1908 in a Phase I clinical trial in the United States.